Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial.

Fiche publication

Date publication

août 2026

Journal

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Auteurs

Membres identifiés du Cancéropôle Est :
Dr EBERST Lauriane

Tous les auteurs :
Jordan SE, González-Martin A, Morlock R, Hubig L, Yonemori K, Eberst L, Zikan M, Kim HS, Banerjee S, Damian F, Salutari V, Henry S, Raimondo M, Kolinsky M, Woelber L, Tromp J, Hietanen S, Nishio S, Lee JY, Manso L, Cruz F, Barraclough L, Oaknin A, Van Nieuwenhuysen E, Randall L, Lo SH, Mutebi A, Abrahami D, Leary A, Vergote I

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42680635

Résumé

In the phase 3, multi-national, open-label, randomized innovaTV 301/ENGOT-cx12/GOG-3057 trial (NCT04697628), tisotumab vedotin as second- or third-line therapy significantly improved survival versus chemotherapy in patients with recurrent or metastatic cervical cancer. We report a post hoc analysis of patient-reported outcomes on health-related quality of life from innovaTV 301.